Scientific Leaders of the project: Neus Ferrer Miralles, PhD.
Coordinator of the project: Paolo Saccardo, PhD.
Insoluble protein aggregates, also known as Inclusion Bodies,long considered a discard product of recombinant protein production, are now being rediscovered for they application in animal and human health mainly for tissue regenerative processes. IBs in fact are non-soluble protein aggregates formed by active proteins which can be released from the IBs aggregates. These materials can be used both for decorating plastic supports in contact with cells, stimulating a cell response depending of the nature of the protein, or can be directly locally injected, providing a sustained release of active therapeutic protein, as has been described for protein hormones accumulated in secretory granules of theen docrine system.
Once again, IBs are easy to produce, cost effective and almost every protein can be produce in this form.
Services involved: Standar services
Projects are carried out essentially by U1 (PPP).Depending of the nature of the proteins, their purifications and characterization can be developed in collaboration with U2 (cAbS).
Protein nanoparticles effectiveness and toxicity can be tested in collaboration of U18 (Nanotoxicology) and experiments in vivo can be performed by U20 (In Vivo Experimental).
These platforms are currently collaborating with U1 (PPP) on projects of this type.
Some examples are described in the following publications:
1: Release of targeted protein nanoparticles from functionalbacterial amyloids: A death star-like approach. Unzueta U, Cespedes MV, Sala R, Alamo P, Sánchez-Chardi A, Pesarrodona M, Sánchez-García L, Cano-Garrido O, Villaverde A, Vázquez E, Mangues R,Seras-Franzoso J. J Control Release. 2018 Apr8;279:29-39. doi: 10.1016/j.jconrel.2018.04.004. [Epub ahead of print] PubMed PMID: 29641987.
Protein nanoparticles are nontoxic, tuneable cell stressors: de PinhoFavaro MT, Sánchez-García L, Sánchez-Chardi A, Roldán M, Unzueta U, Serna N, Cano-Garrido O, Azzoni AR, Ferrer-Miralles N, Villaverde A, Vázquez E..Nanomedicine (Lond). 2018 Feb;13(3):255-268. doi: 10.2217/nnm-2017-0294. Epub 2018 Jan 17. PubMed
Intracellular trafficking of a dynein-based nanoparticle designed for gene
delivery. Favaro MTP, Unzueta U, de Cabo M, Villaverde A, Ferrer-Miralles N, Azzoni AR.
Eur J Pharm Sci. 2018 Jan 15;112:71-78. doi:10.1016/j.ejps.2017.11.002. Epub 2017 Nov 4. PubMed PMID: 29113920.
Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs.Sánchez-García L, Serna N, Álamo P, Sala R, Céspedes MV, Roldan M, Sánchez-Chardi A, Unzueta U, Casanova I, Mangues R, Vázquez E, Villaverde A. J Control Release. 2018 Mar 28;274:81-92. doi: 10.1016/j.jconrel.2018.01.031. Epub 2018 Jan 31. PubMed PMID: 29408658.
Engineering multifunctional protein nanoparticles by in vitro disassembling and reassembling of heterologous building blocksUnzueta U, Serna N, Sánchez-García L, Roldán M, Sánchez-Chardi A, Mangues R,Villaverde A, Vázquez E.Nanotechnology. 2017 Dec 15;28(50):505102. doi: 10.1088/1361-6528/aa963e. PubMed PMID: 29072576.
Unit 1 Protein Production Platform Team. From the left:Dr. Mercedes Marquez,Technician; Dr. Paolo Saccardo,Technical coordinator;Rosa Mendoza, Technician; Dr. Neus Ferrer Miralles, Director/Scientific Coordinator; Dr. Ana ZuleimaObando,Technician.
Unit 1 Protein Production Platform facilities.Purification room with two FPLC AKTA systems.